Mullen was most recently ceo and president at biotechnology firm Biogen Idec, formed from the merger, led Mullen, of Biogen and Idec Pharmaceuticals. Prior to the merger, Mullen was ceo and president of Biogen from 2000 to 2002, and chairman, ceo and president until 2003. Prior to that, he held various operating positions at Biogen, including vice president, Operations.
Peter Bigelow, Patheon’s president of North American Operations, had been acting as interim ceo while the search for the new ceo was conducted.
Patheon hires James Mullen as chief executive
Joins from biotechnology firm Biogen Idec
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
Inside Patheon’s new flexible pharmaceutical development facilities
In the pharmaceutical sector, flexible facilities are in demand as new niche therapies replace traditional blockbusters. Patheon’s Tony Pidgeon, Process Technology Director, and Louise Hall, PMP, Senior Director, Pharmaceutical Development Services, describe improvements made at the company’s new sterile PDS Suite at its Greenville (NC, USA) site to meet the new trend
